Navigation Links
AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

Evaluable 6.4 months 25 months Patients 95% CI (5.3, 7.1) 95% CI (15.5, NR) (n=73) ------------------------------------------------------------------------- NR = Not Reached * Median PFS and median TTP were identical, as no patient deaths occurred prior to progression. ** Kaplan Meier methodology was used to determine overall survival figures.

Of particular interest was the comparison of evaluable patients who were previously refractory and the patients who were relapsed to a bortezomib-based regimen.

    Median PFS and OS for bortezomib relapsed vs. refractory were as follows:

    -------------------------------------------------------------------------
    Bortezomib Relapsed
    vs. Refractory              Median PFS*         Median OS**
    -------------------------------------------------------------------------
    Bortezomib Relapsed         8.8 months            Not Reached at
    (n=20)           95% CI (6.3, 11.2)    38+ months  95% CI
                                                      (25, NR)
    -------------------------------------------------------------------------
    Bortezomib Refractory       5.7 months            22.5 months
    (n=53)           95% CI (4.3, 6.4)     95% CI (12.3, NR)
    -------------------------------------------------------------------------

    * Median PFS and median TTP were identical, as no patient deaths
    occurred prior to progression.
    ** Kaplan Meier methodology was used to determine overall survival
    figures.

No unexpected adverse events have been observed. Toxicities were manageable with supportive care.

"We congratulate our partner Keryx and their principle investigators Dr. Richardson and Dr. Anderson for the encouraging results for perifosine in multiple myeloma which further demonstrate perifosine's potential as a novel treatment for this indication. We now look for
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- An analysis by Replikins, Ltd. of Pubmed data ... virus strains has revealed extensive conservation and sharing ... and sharing of specific Replikin gene structures has permitted ... it did for the H5N1 influenza vaccine and the ... found to be effective (1,2). This ...
(Date:8/26/2014)... Israel , August 26, 2014 ... 3DM, supports NHS hospitals with surgery validation using its Stratasys ... - Performing surgery on 3D printed models prior to ... and provides an effective aid for both patient and surgeon ... SSYS ), a global leader of 3D printing and ...
(Date:8/26/2014)... AVENTURA. Fla. , Aug. 26, 2014 /PRNewswire/ ... trades under the symbol (NUUU) has two (2) ... Inc. Our two subsidiaries harness scientifically advanced technology ... NUUU,s Renuell Int,l, Inc. ... breakthrough anti-aging skin care products that is made ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4
... is becoming more and more a rare option rather than ... still getting feedback about people giving two-weeks' notice and then ... notices no longer are part of the standard practice. , ... , ,One reader said you should give a two-week notice ...
... leaves behind an economic year in which some new investments ... tech economy positioned itself to prosper in some emerging sectors. ... investment climate must remain warm and state policymakers need to ... ability to compete in the global marketplace. What's in store ...
... Dow Jones Industrials had a fabulous year and outperformed ... very solid year, by a large margin. The two key ... because the different composition of each. , ,The NASDAQ Biotech ... greater spectrum of the biotech industry (larger and smaller companies), ...
Cached Biology Technology:Two-week notices: People are still concerned 2Two-week notices: People are still concerned 3Two-week notices: People are still concerned 4Two-week notices: People are still concerned 5Wisconsin's high-growth economy: '07 predictions 2Wisconsin's high-growth economy: '07 predictions 3Wisconsin's high-growth economy: '07 predictions 42006: A mixed blessing for Midwest life science companies 22006: A mixed blessing for Midwest life science companies 32006: A mixed blessing for Midwest life science companies 42006: A mixed blessing for Midwest life science companies 52006: A mixed blessing for Midwest life science companies 62006: A mixed blessing for Midwest life science companies 72006: A mixed blessing for Midwest life science companies 82006: A mixed blessing for Midwest life science companies 92006: A mixed blessing for Midwest life science companies 102006: A mixed blessing for Midwest life science companies 11
(Date:8/26/2014)... a protective tent over a colony of harmful ... especially difficult. Microorganisms protected in a biofilm pose ... resistance and recalcitrance to treatment, and biofilm-protected bacteria ... infections in humans and are 50 to 1,000 ... infections. , "In essence, we may have stumbled ...
(Date:8/26/2014)... Illinois engineers are bringing a touch of color ... new continuous glucose monitoring material that changes color ... is so precise that doctors and patients may ... dosing - something not possible using current ... significant limitations to current continuous glucose monitoring technologies," ...
(Date:8/26/2014)... and optical microresonators, researchers at the University of ... amplifier (or laser) design, paving the way for ... systems at the microscopic scale that amplify light ... Eden, a professor of electrical and computer engineering ... well-suited for routing optical power on a chip ...
Breaking Biology News(10 mins):Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3A glucose meter of a different color provides continuous monitoring 2A glucose meter of a different color provides continuous monitoring 3Symphony of nanoplasmonic and optical resonators produces laser-like light emission 2
... more than 180 research papers suggests fish oils could minimise ... a review by researchers at the University of Liverpool has ... and Chronic Disease reviewed research from around the world to ... omega-3s had a role to play in aiding weight loss. ...
... complex, weight-bearing hips of walking animals from the basic hips ... Tetrapods, or four-legged animals, first stepped onto land about ... by strong hipbones and a connection through the spine via ... fish ancestors of tetrapods. In a study published ...
... Biotechnology (DBT) and Bharat Biotech announced positive results from ... developed and manufactured in India. Data from the trial, ... for IndiaThe Evidence and the Promise, showed ROTAVAC to ... The clinical study demonstrates for the first time that ...
Cached Biology News:Fish oil may stall effects of junk food on brain 2From ocean to land: The fishy origins of our hips 2Rotavirus vaccine developed in India demonstrates strong efficacy 2Rotavirus vaccine developed in India demonstrates strong efficacy 3Rotavirus vaccine developed in India demonstrates strong efficacy 4
... Have you bought a Perkin Elmer UltraVIEW system ... the Andor iXon and iQ software? No problem. ... upgrade. You keep your existing microscope, lasers, Sutter ... customise it to work with our precision controller ...
...
... is a 96-well ELISA-compatible plate (containing 12 x ... Monoclonal Antibody is immobilized by a method that ... the tail fiber protein of the T7 bacteriophage. ... 10 9 phage per well and low ...
... The TRAPeze RT Telomerase Detection ... in vitro assay for the ... quantification of telomerase activity. It ... TRAPeze assay and adds the ...
Biology Products: